16 September 2026 editorial review · Item
Ain Shams adipose-derived insulin-producing cells: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: new record; substantive review 16 September 2026.
- Scope and findings: Added specific Ain Shams university protocol. Checked autologous adipose collection, differentiation intent, portal versus peripheral delivery, target 20 adolescents and sponsor-entered Phase 2/3. Visible text distinguishes registered phase from demonstrated pivotal maturity.
- Primary sources checked: NCT06951074 — study record (registry).
- Limits: April 2025 record remains recruiting despite passed estimated completion dates. No reported insulin independence, engraftment durability, safety dataset or validated immune-protection strategy. Not linked to commercial clinics or sold as a treatment.